- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.10. | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 08.10. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09. | Nasus Pharma stock reiterated at Market Outperform by Citizens | 1 | Investing.com | ||
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.09. | Nasus Pharma: Citizens bestätigt "Market Outperform" nach Studienfortschritt | 4 | Investing.com Deutsch | ||
| 29.09. | Nasus Pharma, Ltd.: Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron | 289 | GlobeNewswire (Europe) | TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 14.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.09. | Nasus Pharma, Ltd.: Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis | 349 | GlobeNewswire (Europe) | Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration... ► Artikel lesen | |
| 04.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.08. | Nasus Pharma Targets Q4 Pivotal Study For Intranasal Epinephrine In $2 Billion Market, With Topline Data Expected Q1 2027 | 1 | pulse2.com | ||
| 19.08. | Nasus Pharma CFO Eyal Rubin to depart in September | 1 | Investing.com | ||
| 19.08. | Nasus Pharma CFO Eyal Rubin to leave | 2 | Seeking Alpha | ||
| 19.08. | Nasus Pharma, Ltd.: Nasus Pharma Announces Transition of Chief Financial Officer | 397 | GlobeNewswire (Europe) | TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development... ► Artikel lesen | |
| 17.08. | Nasus Pharma 1H non-GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
| 17.08. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.08. | Nasus Pharma, Ltd.: Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update | 539 | GlobeNewswire (Europe) | Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE... ► Artikel lesen | |
| 28.07. | Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman | 1 | RTTNews | ||
| 28.07. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.07. | Nasus Pharma names Brendan O'Grady as new CEO | 1 | Investing.com | ||
| 28.07. | Nasus Pharma, Ltd.: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | 368 | GlobeNewswire (Europe) | TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 18,422 | -1,39 % | Viatris Inc. Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Viatris Inc. (VTRS):Earnings: -$325.3 million in Q3 vs. -$128.2 million in the same period last year.
EPS: -$0.28 in Q3 vs. -$0.11... ► Artikel lesen | |
| SYNBIOTIC | 0,113 | -2,41 % | SYNBIOTIC SE: Zuvor aufgezeigte Risiken haben sich materialisiert; Rating und Kursziel under review | SYNBIOTIC hat angekündigt, einen Insolvenzantrag zu stellen, nachdem es dem Unternehmen angesichts anhaltend schwieriger Marktbedingungen nicht gelungen ist, eine ausreichende Finanzierung sicherzustellen.... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,763 | -0,26 % | Organigram: Aurora Cannabis Acquisition Valued At C$561 Million To Create Global Cannabis Platform | ||
| QUANTUM BIOPHARMA | 1,781 | +5,26 % | Quantum Biopharma Ltd: Quantum Biopharma shareholders approve AGM resolutions | ||
| NEKTAR THERAPEUTICS | 33,230 | -1,80 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 3,788 | +2,74 % | Tonix Q3 2026 slides: TONMYA sales up 37%, shares fall on loss | ||
| ORAMED PHARMACEUTICALS | 3,520 | +0,28 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,480 | -0,27 % | Sellas Life Sciences Group: Regal-Studie erreicht die nächste Marke, aber die Aktie fällt - vor der Schlussanalyse | ||
| OPKO HEALTH | 1,550 | +0,65 % | Opko sees FY 2026 continuing-ops revenue of $268M-$278M following $722M LabCorp asset sale agreement | ||
| JAGUAR HEALTH | 0,437 | +0,07 % | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders | SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special Meeting... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,712 | +6,11 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen | |
| OPUS GENETICS | 3,780 | -1,05 % | Citizens reiterates Opus Genetics stock rating on pipeline progress | ||
| SOLIGENIX | 0,320 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results | PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare... ► Artikel lesen | |
| TALPHERA | 1,000 | +5,26 % | Talphera Q3 2026 Earnings Preview | ||
| SAVARA | 4,537 | +2,83 % | H.C. Wainwright initiates Savara stock coverage with buy rating |
Das Unternehmen NASUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,05 % bei einem Aktienkurs von 2,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.